Terry Fife, MD
Neurology · Phoenix, AZNPI 1346248390
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $875 of the $1,346 with a category attached, or 65.0%. Biohaven Pharmaceutical Holding Company Ltd. accounts for 65.0% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2022 at $1,182 and has fallen 97.6% since, to $28 in 2023. That places this record below the midpoint for neurology clinicians in AZ, where the typical reported total is $1,232.
Across 6 payments — averaging $224.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biohaven Pharmaceutical Holding Company Ltd.$875
- AstraZeneca$263
- E.r. Squibb & Sons, L.L.C.$122
- Biosense Webster, Inc.$58
- GT Medical Technologies, Inc$28
Across 24 payments — averaging $4340.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biohaven Pharmaceuticals, Inc.$66K
- Biohaven Pharmaceutical Holding Company Ltd.$38K
What the payments were for
- Consulting fees$87565%
- Food & beverage$47135%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $875 |
| AstraZeneca(2 entities) | 2 | $263 |
| E.r. Squibb & Sons, L.L.C. | 1 | $122 |
| Biosense Webster, Inc. | 1 | $58 |
| GT Medical Technologies, Inc | 1 | $28 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,346 in reported general payments places this provider in the 50th percentile of 388 neurology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 16 | $19,684 |
| Emgality PenGalcanezumab-Gnlm | 18 | $12,855 |
| Verapamil ErVerapamil Hcl | 58 | $1,545 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 85 | $1,268 |
| Sumatriptan Succinate | 37 | $605 |
| Nortriptyline Hcl | 23 | $568 |
| Gabapentin | 38 | $548 |
| Verapamil SrVerapamil Hcl | 14 | $421 |
| RizatriptanRizatriptan Benzoate | 23 | $371 |
| Topiramate | 23 | $306 |
| Imipramine Hcl | 20 | $252 |
| Baclofen | 13 | $251 |
| Diazepam | 50 | $245 |
| Lamotrigine | 25 | $233 |
| Clonazepam | 27 | $176 |
Paid to pharmacies, not to this prescriber.
Other neurology in Phoenix
- Barry HendinPhoenix$2.3M
- Maria OspinaPhoenix$2.1M
- Suraj MuleyPhoenix$1.7M
- Eric ErossPhoenix$778K
- Steve ChungPhoenix$685K
- Marwan SabbaghPhoenix$603K
- Kerry KnievelPhoenix$509K
- Lori TravisPhoenix$406K
- Jeffrey GittPhoenix$275K
- Todd SchwedtPhoenix$273K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.